Who founded Serenatis Bio?

Serenatis Bio was founded by Nick Sireau, David Cavalla.

Who are Serenatis Bio's investors?

Serenatis Bio's investors include P53 Invest, Zinc.

Where is Serenatis Bio headquartered?

Serenatis Bio is headquartered in Cambridge, GB.

Serenatis Bio

Cambridge, GB · 2 known investors

Find your way into Serenatis Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Serenatis Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options. The company's pipeline includes three novel candidates designed to work faster and with fewer side effects than existing medications.

Biotech Mental Health

Founders & leadership

Nick Sireau Executive Chairman & Co-founderNick Sireau is co-founder and executive chairman of Serenatis Bio, a Cambridge-based biotech developing small-molecule treatments for obsessive-compulsive disorder and other compulsive disorders. He previously led drug development efforts at the AKU Society, bringing nitisinone through clinical trials for alkaptonuria, and co-founded Orchard OCD, a non-profit organization focused on OCD research.

David Cavalla CEO & Co-founderHe has held executive roles in biotechnology and pharmaceuticals, authored a book on preclinical R&D strategy, and has published over 70 papers and patents in pharmaceutical development and strategy.

Investors · 2

P53 Investlisted by P53 InvestStavanger

How we know: P53 Invest's portfolio page · Not right? Tell us

ZincreportedLondon

How we know: funding news · Not right? Tell us

Companies House · registry record

View on Companies House ↗

Registered name: SERENATIS BIO LIMITED
Company number: 15944501
Status: Active
Company type: Private limited company
Incorporated: 9 Sept 2024
Registered office: 66 Devonshire Road, Cambridge, CB1 2BL
Nature of business (SIC): 72110 — Research and experimental development on biotechnology
Accounts: last made up to 30 Sept 2025 · next due 30 Jun 2027
Confirmation statement: last made up to 8 Sept 2025 · next due 22 Sept 2026

Current officers · 4

David John Cavalla — director, appointed 9 Sept 2024
Natalie Pankova — director, appointed 9 May 2025
Nicolas Thierry Sireau — director, appointed 9 Sept 2024
Susanne Stuffers — director, appointed 9 May 2025

Source: Companies House public register · retrieved 5 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Serenatis Bio do?: Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options. The company's pipeline includes three novel candidates designed to work faster and with fewer side effects than existing medications.
Who founded Serenatis Bio?: Serenatis Bio was founded by Nick Sireau, David Cavalla.
Who are Serenatis Bio's investors?: Serenatis Bio's investors include P53 Invest, Zinc.
Where is Serenatis Bio headquartered?: Serenatis Bio is headquartered in Cambridge, GB.